

Notice: This is a translation of a notice in Japanese and is made solely for the convenience of foreign shareholders.

In the case of any discrepancy between the translation and the Japanese original, the latter shall prevail.

(Translation)

November 5, 2024

To Shareholders,

Company Name: Renaissance Inc.

Representative: Keisuke Furuta, President & CEO

(Code: 4889 TSE Growth)

For inquiries, please contact Administration Dept.

Notice of the completion of a joint development agreement with Taipei Medical University (TMU)-Biotech Co., Ltd. (Taipei) for the PAI-1 inhibitor RS5614.

We are pleased to announce that we have concluded a joint development agreement with Taipei Medical University (TMU)-Biotech Co., Ltd., a wholly owned subsidiary of Taipei Medical University, for the clinical and business development of the PAI-1 inhibitor RS5614.

In order to jointly commercialize the AI-utilizing program medical devices pipeline, Renaissance and TMU-Biotech Co., Ltd. agreed to the "Announcement of the joint R&D collaboration agreement for artificial intelligence (AI)-based software as a medical device (SaMD) with Taipei Medical University (TMU)-Biotech Co., Ltd." and disclosed it on August 30, 2024. We have now agreed to further expand our collaboration to the pharmaceutical development business and collaborate on the clinical development and commercialization of the PAI-1 inhibitor RS5614 in Taipei.

Currently, clinical trials (investigator-initiated clinical trials) for RS5614 in Japan are being conducted for chronic myeloid leukemia (CML: early and late phase II trials completed, phase III trials ongoing), malignant melanoma (melanoma: phase II trials completed, phase III trials in preparation), non-small cell lung cancer (phase II trials ongoing), and cutaneous angiosarcoma (phase II trials ongoing) in the cancer field, and for lung injury associated with COVID-19 (early and late phase II trials completed), interstitial lung disease associated with systemic sclerosis (phase II trials ongoing), and interstitial pneumonia caused by anticancer drugs (non-clinical trials planned) in respiratory diseases.

TMU-Biotech is a wholly owned subsidiary of Taipei Medical University (TMU) (<https://eng.tmu.edu.tw>) with the aim of commercializing medical seeds researched and developed at TMU. TMU was established in 1960 and is one of the top private medical universities in Taipei, with 3,000 beds.

We view the overseas expansion of RS5614 as a very important strategy, and hope to use the clinical development and commercialization in Taipei as a foothold for further expansion overseas.

At present, this matter has no particular impact on our business performance.